Neoadjuvant immunotherapy in nonsmall cell lung cancer

Area of Science:

• Oncology
• Immunotherapy
• Thoracic Surgery

Background:

• Immune-checkpoint inhibitors (ICIs) have advanced metastatic non-small cell lung cancer (NSCLC) treatment.
• Research is exploring ICI efficacy in earlier stages of NSCLC.
• Neoadjuvant immunotherapy, given before surgery, is a key area of investigation.

Purpose of the Study:

• To review the background and early clinical evidence for neoadjuvant immunotherapy in NSCLC.
• To discuss future directions for neoadjuvant immunotherapy in NSCLC treatment.

Main Methods:

• Review of preclinical data and early clinical trials.
• Analysis of pathologic and radiographic regression rates.
• Assessment of toxicity profiles and surgical outcomes.

Main Results:

• Neoadjuvant immunotherapy, especially combined with chemotherapy, shows promising efficacy in early-stage NSCLC.
• Improved pathologic and radiographic regression rates observed compared to historical controls.
• Moderate toxicity and no impairment of surgical outcomes reported.

Conclusions:

• Neoadjuvant immunotherapy holds significant potential to enhance outcomes for early-stage NSCLC.
• This approach may lead to changes in standard clinical practice.
• Further evidence from ongoing phase III trials is anticipated.